Lab
American Forensic Toxicology Services LLC
American Forensic Toxicology Services LLC was paid $33.21M by Medicaid between Jan 2018 and Dec 2024, across 56 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 45% of everything it billed.
33Billing provider infoAMERICAN FORENSIC TOXICOLOGY SERVICES LLC
HUNTINGTON, NY 11743
HUNTINGTON, NY 11743
33aNPI1417283623assigned 10/22/2009
33bProvider typeClinical Medical Laboratory
28Total paid$33.21M
24GClaims1,096,542
24DCodes billed56
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in New York
Rank by total paid#12 of 116
Median peer was paid$618K
This provider vs. median54×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 300,684 | $11.74M | |
| 2019 | 206,969 | $5.15M | |
| 2020 | 148,898 | $4.29M | |
| 2021 | 168,848 | $4.98M | |
| 2022 | 119,922 | $3.00M | |
| 2023 | 92,662 | $2.00M | |
| 2024incomplete | 58,559 | $2.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 45% | 401,478 | 221,921 | $14.94M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 34% | 304,883 | 174,510 | $11.25M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 9.9% | 53,559 | 36,884 | $3.30M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 7.8% | 45,163 | 25,628 | $2.58M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.1% | 3,650 | 2,596 | $364K |
| 80346 | <1% | 24,700 | 14,058 | $80K | |
| 80348 | <1% | 19,510 | 15,166 | $55K | |
| 80361 | <1% | 20,326 | 12,452 | $53K | |
| 80365 | <1% | 18,817 | 12,262 | $51K | |
| 80355 | <1% | 10,959 | 8,434 | $32K | |
| 80358 | <1% | 12,811 | 8,918 | $31K | |
| 80349 | <1% | 11,504 | 8,140 | $31K |
44 more codes
| 80354 | <1% | 10,682 | $30K | |
| 80353 | <1% | 10,246 | $27K | |
| 80357 | <1% | 8,087 | $27K | |
| 80325 | <1% | 7,794 | $25K | |
| 80356 | <1% | 7,406 | $19K | |
| 80362 | <1% | 6,354 | $19K | |
| 80359 | <1% | 7,306 | $18K | |
| 80338 | <1% | 5,296 | $18K | |
| 80360 | <1% | 9,953 | $18K | |
| 80323 | <1% | 6,850 | $17K | |
| 83992 | <1% | 4,901 | $17K | |
| 80333 | <1% | 4,293 | $16K | |
| 80372 | <1% | 6,650 | $15K | |
| 81025 | <1% | 2,618 | $14K | |
| 80373 | <1% | 6,126 | $14K | |
| 80366 | <1% | 4,876 | $14K | |
| 80337 | <1% | 4,116 | $13K | |
| 80364 | <1% | 6,067 | $13K | |
| 80368 | <1% | 7,068 | $11K | |
| 82570 | <1% | 2,617 | $11K | |
| 80369 | <1% | 5,961 | $10K | |
| 80371 | <1% | 4,752 | $10K | |
| 83986 | <1% | 1,885 | $10K | |
| 80324 | <1% | 3,429 | $10K | |
| 80367 | <1% | 2,924 | $7K | |
| 80321 | <1% | 3,062 | $6K | |
| 80320 | <1% | 1,315 | $5K | |
| 80345 | <1% | 2,270 | $4K | |
| 80332 | <1% | 2,092 | $4K | |
| 80363 | <1% | 1,280 | $4K | |
| 80336 | <1% | 1,232 | $3K | |
| 80352 | <1% | 1,240 | $3K | |
| 80305 | <1% | 718 | $2K | |
| 80342 | <1% | 1,810 | $2K | |
| 80171 | <1% | 171 | $1K | |
| 80374 | <1% | 563 | $1K | |
| 84311 | <1% | 934 | $684.86 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 859 | $389.11 |
| 80343 | <1% | 403 | $385.61 | |
| 81003 | <1% | 820 | $327.87 | |
| 80375 | <1% | 1,498 | $180.00 | |
| 80339 | <1% | 272 | $149.14 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 349 | $23.58 |
| 80341 | 0% | 37 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFREEMAN, SYLVIA (MGR OF CREDENTIALING/ENROLLMENT)
| Provider | Location | Paid |
|---|---|---|
| Regional Toxicology Services, LLC | Tacoma, WA | $60.35M |
| Secon of New England LLC | Worcester, MA | $8.88M |
| Rocky Mountain Tox, LLC | Aurora, CO | $236K |
| Technical Resource Management LLC | Indianapolis, IN | $119.72 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.